Publication | Open Access

A phase III randomized, double-blind, placebo-controlled trial of the denosumab biosimilar QL1206 in postmenopausal Chinese women with osteoporosis and high fracture risk

Bone DiseaseBone HealthPhase IiiPlacebo-controlled TrialMenopauseBone DensityDenosumab Biosimilar Ql1206MedicineOsteoporosisRheumatoid ArthritisWomen's Health